<DOC>
	<DOC>NCT00255645</DOC>
	<brief_summary>This is a long-term safety follow-up study to assess the post-treatment safety, at 12 and 24 months, in patients with type 2 diabetes after participation in the phaseII/III studies GALLANT, GALLEX and ARMOR. In addition, selected patients, including those with pre-defined laboratory or clinical findings, will have a 12-week post-treatment follow-up visit, including laboratory evaluation and adverse event recording.</brief_summary>
	<brief_title>G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Provision of a written informed consent Men or women who either completed at least 6 months in a previous treatment study GALLANT, GALLEX or ARMOR or met a predefined laboratory or clinical finding during participation in any of the said studies. Received openlabel treatment with tesaglitazar (since this is a posttreatment study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>